GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Qualigen Therapeutics Inc (NAS:QLGN) » Definitions » Market Cap

QLGN (Qualigen Therapeutics) Market Cap : $2.30 Mil (As of Mar. 19, 2025)


View and export this data going back to 2020. Start your Free Trial

What is Qualigen Therapeutics Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Qualigen Therapeutics's share price for the quarter that ended in Sep. 2024 was $8.525. Qualigen Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Sep. 2024 was 0.55 Mil. Therefore, Qualigen Therapeutics's market cap for the quarter that ended in Sep. 2024 was $4.67 Mil.

Qualigen Therapeutics's quarterly market cap declined from Mar. 2024 ($2.60 Mil) to Jun. 2024 ($1.65 Mil) but then increased from Jun. 2024 ($1.65 Mil) to Sep. 2024 ($4.67 Mil).

Qualigen Therapeutics's annual market cap declined from Dec. 2021 ($37.99 Mil) to Dec. 2022 ($5.41 Mil) and declined from Dec. 2022 ($5.41 Mil) to Dec. 2023 ($2.94 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Qualigen Therapeutics's Enterprise Value for Today is $3.40 Mil.


Qualigen Therapeutics Market Cap Historical Data

The historical data trend for Qualigen Therapeutics's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Qualigen Therapeutics Market Cap Chart

Qualigen Therapeutics Annual Data
Trend Mar20 Dec21 Dec22 Dec23
Market Cap
- 37.99 5.41 2.94

Qualigen Therapeutics Quarterly Data
Sep19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.10 2.94 2.60 1.65 4.67

Competitive Comparison of Qualigen Therapeutics's Market Cap

For the Biotechnology subindustry, Qualigen Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Qualigen Therapeutics's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Qualigen Therapeutics's Market Cap distribution charts can be found below:

* The bar in red indicates where Qualigen Therapeutics's Market Cap falls into.



Qualigen Therapeutics Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Qualigen Therapeutics's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )=Share Price (A: Dec. 2023 )*Shares Outstanding (EOP) (A: Dec. 2023 )
=$27.5*0.107
=$2.94

Qualigen Therapeutics's Market Cap for the quarter that ended in Sep. 2024 is calculated as

Market Cap (Q: Sep. 2024 )=Share Price (Q: Sep. 2024 )*Shares Outstanding (EOP) (Q: Sep. 2024 )
=$8.525*0.548
=$4.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Qualigen Therapeutics  (NAS:QLGN) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Qualigen Therapeutics Market Cap Related Terms

Thank you for viewing the detailed overview of Qualigen Therapeutics's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


Qualigen Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
5857 Owens Avenue, Suite 300, Carlsbad, CA, USA, 92008
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.
Executives
Michael S. Poirier director, officer: Chairman, President and CEO 2042 CORTE DEL NOGAL, SUITE B, CARLSBAD CA 92011
Amy S. Broidrick director 1440 VALLE GRANDE, ESCONDIDO CA 92025
Kurt H Kruger director 100 FOXBOROUGH BLVD, SUITE 240, FOXBOROUGH MA 02035
Tariq Arshad officer: SVP/Chief Medical Officer 2042 CORTE DEL NOGAL, SUITE B, CARLSBAD CA 92011
Christopher L. Lotz officer: Vice President of Finance, CFO 2042 CORTE DEL NOGAL, SUITE B, CARLSBAD CA 90211
Emery Sidney W Jr director C/O QUALIGEN THERAPEUTICS, INC., 2042 CORTE DEL NOGAL, CARLSBAD CA 92011
Richard A. David director 2042 CORTE DEL NOGAL, SUITE B, CARLSBAD CA 92011
Wajdi Abdul-ahad officer: VP, R&D, CSO 2042 CORTE DEL NOGAL, SUITE B, CARLSBAD CA 92011
Shishir K. Sinha officer: VP of Operations 2042 CORTE DEL NOGAL, SUITE B, CARLSBAD CA 92011
Sekisui Diagnostics, Llc 10 percent owner 1 WALL STREET, BURLINGTON MA 01803
Matthew E Korenberg director 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Noah Doyle director C/O RITTER PHARMACEUTICALS INC., 1801 CENTURY PARK EAST, SUITE 1820, LOS ANGELES CA 90096
John W Beck officer: Chief Financial Officer C/O RITTER PHARMACEUTICALS, INC., 1880 CENTURY PARK EAST, SUITE 1000, LOS ANGELES CA 90067
Jeffrey S Benjamin officer: VP of Finance 3885 CRESTWOOD PARKWAY, SUITE 550, DULUTH GA 30096
William M. Merino director C/O RITTER PHARMACEUTICALS INC., 1880 CENTURY PARK EAST, SUITE 1000, LOS ANGELES CA 90067